CALGB C80702
Disease Stage: 3
Status: Recruiting patients
Sponsor: Cancer and Leukemia Group B (CALGB)
Title: Clinical Trial of 6 vs. 12 treatments of adjuvant FOLFOX + celecoxib or placebo for patients with resected stage 3 colon cancer.
Phase: 3
Purpose: To compare the disease free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.
Eligibility:
- Completely resected stage III colon cancer
- No invasive cancer in last 5 years
- No residual disease
- Good performance status
- No cardiac risk factors
Contact: 772-288-5858, option 4
Contact Us
Robert and Carol Weissman Cancer Center
Clinical Research Program
501 E. Osceola St.
Stuart, FL 34994
(772) 288-5858, prompt #4
Email Us